about
Early life programming as a target for prevention of child and adolescent mental disordersSpecific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataOxidative stress and mitochondrial dysfunction across broad-ranging pathologies: toward mitochondria-targeted clinical strategies.Genetic basis of congenital cardiovascular malformationsCongenital Malformations and Consequential Epidemiology.Human teratogens update 2011: can we ensure safety during pregnancy?Medication use among pregnant women with systemic lupus erythematosus and general population comparators.Systematic procedure for the classification of proven and potential teratogens for use in research.Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma.Most Frequently Reported Prescription Medications and Supplements in Couples Planning Pregnancy: The LIFE Study.Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011.Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation.Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists.Discussing Appropriate Medication Use and Multivitamin Intake with a Healthcare Provider: An Examination of Two Elements of Preconception Care Among Latinas.Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011.ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects.
P2860
Q21245282-2B80CC16-06DD-479B-A703-DAF8ECAE2815Q30979346-0AF1D862-FE19-43DF-9E99-D4567CA786D2Q31115877-12C372D1-9C89-4678-8712-687221B2EEAFQ33625254-EA64EA16-AB0C-4E3C-9ADC-4EC441BF414BQ34125381-B9B909E9-0523-4EBC-9C81-63F32F060152Q35077898-AE6F61D3-FC9D-4DD3-B049-7E8114879DE1Q35815011-A833DABC-35F0-46A2-9261-5C9776ABBDB4Q40408617-B454CFE9-1479-4FEF-BF16-0C38C277F969Q40857819-C9430931-9A35-41C2-BBA5-AFA8731218BBQ43576495-BFB6B428-A86F-4F8E-8C1B-36332314CA10Q44319492-F12ECAC8-6CCE-4448-88C7-97989AAC3520Q44580295-6B0FB8E8-3023-4CC7-8C91-608489C40BEEQ46639978-978357C5-35B4-4120-B1D4-2989EF6E25FBQ47316435-70F16C41-C519-42EF-B4E2-CBC1FC6976CEQ47596888-A5E595D4-AB46-4358-B466-BE461CA809A1Q47833785-D1F323E6-7CBC-47BF-AB56-192124252A65Q50796372-84BAE721-7275-442C-BFCD-5CD8B942909B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Teratogenic exposures.
@en
Teratogenic exposures.
@nl
type
label
Teratogenic exposures.
@en
Teratogenic exposures.
@nl
prefLabel
Teratogenic exposures.
@en
Teratogenic exposures.
@nl
P2860
P356
P1476
Teratogenic exposures.
@en
P2093
Anthony R Scialli
Sarah Običan
P2860
P304
P356
10.1002/AJMG.C.30310
P577
2011-07-15T00:00:00Z